Domestic Import zoledronic acid treatment of malignant bone metastasis pain suppressing effect of cost comparison.docVIP

 PAGE \* MERGEFORMAT 9 Domestic Import zoledronic acid treatment of malignant bone metastasis pain suppressing effect of cost comparison 【Abstract】 Objective To compare the domestic and imported zoledronic acid injection in treatment of malignant bone metastasis cost - effectiveness ratio. Methods 178 cases of malignant tumors in patients with bone metastases were randomly divided into two groups, 93 cases of the use of domestic zoledronic acid injection, 85 cases of the use of imported zoledronic acid injection, repeated every 4 weeks using a time. To compare the two groups to improve the rate and quality of life in patients with the incidence of adverse reactions. The results of domestic zoledronic acid injection of zoledronic acid and imported injection in the quality of life improvement rate were 37.63% (35/93) and 42.35% (36/85) in the incidence of adverse reactions were 22.58% (21/93) and 23.53% (20/85), no statistically significant difference between the two. Conclusions Cost - effectiveness ratio showed that domestic imports of zoledronic acid of zoledronic acid compared with the low. Keywords: quality of life of zoledronic acid, adverse reactions cost - effectiveness ratio 【Abstract】 Objective To make a comparison study on the ratio of costs to effect of treating malignant tumor bone metastases with Zoledronic acid injection between China-made and imported.Methods The patients with the disease of malignant tumor bone metastases were divided into two groups and treated them with the Zoledronic acid injection of with either China-made and imported respectively every four weeks. After that, the improvement of life quality and the incidence of adverse reactions on the patients fromthe two groups were observed. Results The improvement of life quality by the China-made Zoledronic acid injection was 37.63% (35/93) and that was 42.35% (36/85) by the imported injection. The incidence of adverse reactions on the injection was 22.58% (21/93)